GlassScriptPhysician profile
David M Slotin
NPI 1407824378
$5,355.58
in general payments reported to CMS, 2019-2025
29 companies · $2,473 in 2025
The $2,473 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $93.84 · 2022: $748 · 2023: $1,021 · 2024: $1,020 · 2025: $2,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,513.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $998.12 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $709.83 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $652.01 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $576.46 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $351.95 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $259.59 | 2022-2025 | |
| Astellas Pharma US INC | $191.77 | 2025 | Veozah |
| Exact Sciences Corporation | $165.49 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.29 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $142.71 | 2022-2025 | |
| Inspire Medical Systems, INC. | $137.89 | 2024-2025 | Inspire |
| Dexcom, INC. | $130.69 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Idorsia Pharmaceuticals US INC | $117.32 | 2022-2025 | Quviviq, Quviviq |
| Novartis Pharmaceuticals Corporation | $95.26 | 2022-2023 | |
| Esperion Therapeutics, INC. | $88.30 | 2021-2025 | Nexletol |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $88.20 | 2023-2024 | Otezla, Repatha, Krystexxa |
| Merck Sharp & Dohme LLC | $80.87 | 2021-2023 | Pneumovax 23, M-M-R II, Vaxneuvance |
| Abbott Laboratories | $66.63 | 2022-2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.43 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $55.90 | 2021-2023 | Austedo |
| Dynavax Technologies Corporation | $36.65 | 2023-2024 | Heplisav-B |
| Actelion Pharmaceuticals US, INC. | $33.62 | 2025 | Opsumit, Uptravi |
| Corcept Therapeutics | $31.13 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $26.98 | 2023 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $26.47 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.85 | 2025 | Xifaxan |
| Supernus Pharmaceuticals, INC. | $15.82 | 2022 | |
| Heartflow, INC. | $15.73 | 2022 | |
| Currax Pharmaceuticals LLC | $15.62 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Slotin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.